Aktienanalyse zu Lexaria Bioscience Corp (LEXX)LEXXLexaria Bioscience Corp

Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The Company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Lexaria Bioscience Corp (LEXX) is currently not a good buy due to its recent price target cut to $1.5 and a significant 22.11% decline over the past year. The stock's RSI is at 49.685, suggesting it is neither overbought nor oversold, but the negative sentiment from analysts and the company's ongoing losses indicate caution is warranted.